images/About_IAVI/kavi-researchers-testtubes-overhead.jpgResearchers examine samples at the Kenya AIDS Vaccine Initiative, an IAVI partner clinical research center in Nairobi, Kenya. Photo credit: Sokomoto Photography

The International AIDS Vaccine Initiative (IAVI) is a nonprofit scientific organization whose mission is to develop vaccines and other biomedical innovations that prevent HIV infection. Since its founding in 1996, IAVI has provided scientific and policy leadership to address the needs of communities and key populations at risk for HIV infection around the world. IAVI works with more than 100 academic, industry, government, civil society, clinical, and community partners in more than 25 countries. IAVI is committed to supporting the broad field of HIV vaccine research and to fostering collaborations that accelerate the development and availability of new prevention products. In pursuit of our goals, we work to catalyze and support partnerships, engaging partners from both the public and private sectors across the product development continuum.

Learn more about IAVI’s founding and history.

IAVI’s global reach, including its clinical research network in five countries in sub-Saharan Africa and in India, has allowed IAVI to make fundamental contributions to understanding the epidemiology, transmission, virology, and immunology of HIV. This work played a key role in facilitating the design of promising HIV vaccine candidates, as well as the discovery of broadly neutralizing antibodies that are now being advanced as promising approaches for HIV prevention. IAVI’s integrated capabilities in vaccine discovery, development, and clinical research take advantage of biopharmaceutical industry expertise to accelerate the development and testing of novel HIV vaccine candidates.

In addition to its core HIV vaccine effort, IAVI is working with partners to address other urgent unmet public health needs, for which our existing technologies, assets, and experience can add value.

Overall, IAVI:

  • Pursues promising approaches to vaccines design and development, as well as other ways to prevent HIV.
  • Accelerates vaccine candidates to the clinic through laboratories in the U.S., India, Africa, and the U.K.
  • Engages with at-risk populations and strengthens in-country vaccine research capacity through our network of clinical research partners in Africa.
  • Partners with leading scientists in academia, government, and industry in the U.S. and Europe, applying biopharma product development expertise to develop novel products tailored to the needs of at-risk populations.
  • Supports external researchers with technical and scientific expertise to accelerate vaccine development.
  • Applies its expertise in vaccine and monoclonal antibody discovery and development to addressing other global health challenges.

Financial and Operational Highlights

  • Approximately 200 employees (~80 located at Headquarters in New York City).
  • Offices in Amsterdam, New York City, Johannesburg, Cape Town, Delhi, and Nairobi along with laboratories in La Jolla, London, Delhi, and Brooklyn.
  • Total revenue of $100.6 million.